Merrimack Pharmaceuticals Accounts Payables | MACK

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Merrimack Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
74 K	188 K	120 K	123 K	271 K	1.03 M	2.89 M	2.69 M	3.85 M	2.51 M	1.89 M	283 K	4.66 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.66 M	74 K	1.58 M

Quarterly Accounts Payables Merrimack Pharmaceuticals

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
168 K	74 K	111 K	80 K	89 K	188 K	67 K	84 K	177 K	120 K	104 K	173 K	108 K	123 K	50 K	208 K	839 K	271 K	710 K	24 K	841 K	1.03 M	953 K	1.75 M	2.56 M	2.89 M	8.84 M	8.3 M	7.5 M	2.69 M	8.11 M	12 M	10.8 M	3.85 M	6.24 M	6.78 M	9.7 M	2.51 M	2.64 M	4.32 M	5.45 M	1.89 M	7.36 M	4.73 M	6.46 M	283 K	771 K	2.74 M	2.6 M	4.66 M	4.66 M	4.66 M	4.66 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
12 M	24 K	3 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
AbbVie ABBV	3.59 B	$ 263.04	0.49 %	$ 465 B	USA
Aclaris Therapeutics ACRS	13.2 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	9.18 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Evelo Biosciences EVLO	1.76 M	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	5.49 M	-	-	$ 28.6 M	USA
Checkmate Pharmaceuticals CMPI	3.38 M	-	-	$ 231 M	USA
Clovis Oncology CLVS	27.3 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	3.94 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	2.61 M	-	-	$ 401 M	USA
ADMA Biologics ADMA	22.5 M	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	2.12 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	15.4 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	10.1 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	1.86 M	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	614 K	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	500 K	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	3.82 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	3.99 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	4.71 M	-	-	$ 763 M	USA
Humanigen HGEN	40.5 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	8.69 M	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	14.2 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	983 K	-	-	$ 76.9 M	USA
Intra-Cellular Therapies ITCI	26.1 M	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	2.03 M	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	9.75 M	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	5.67 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	2.4 M	-	1.49 %	$ 50.8 M	USA
Karuna Therapeutics KRTX	6.78 M	-	-	$ 12.2 B	USA
Landos Biopharma LABP	1.38 M	-	0.58 %	$ 144 M	USA
La Jolla Pharmaceutical Company LJPC	2.28 M	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	718 K	-	-	$ 229 M	USA
Lumos Pharma LUMO	890 K	-	-	$ 35.3 M	USA
Stealth BioTherapeutics Corp MITO	3.47 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	18.1 M	-	-	$ 3.3 B	USA
NexImmune NEXI	1.34 M	-	70.13 %	$ 4.12 M	USA
9 Meters Biopharma NMTR	5.05 M	-	-42.97 %	$ 1.05 M	USA
InVivo Therapeutics Holdings Corp. NVIV	617 K	-	-37.48 %	$ 476 K	USA
Oncorus ONCR	5.69 M	-	-8.54 %	$ 3.19 M	USA
Oncternal Therapeutics ONCT	1.15 M	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	315 K	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	9.32 M	-	1.02 %	$ 90.8 M	Britain